Lataa...

An Open-Label Tolerability and Actual-Use Human Factors Study of Etrolizumab Autoinjector in Healthy Volunteers

INTRODUCTION: Etrolizumab is a novel, dual-action, anti-β7 integrin antibody in development for patients with moderate to severe ulcerative colitis or Crohn’s disease. Phase 3 studies use a prefilled syringe (PFS) for etrolizumab administration. In parallel, an autoinjector (AI) is being developed t...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Adv Ther
Päätekijät: Tyrrell, Helen, Ravanello, Renato, Pulley, Jennifer, Tang, Meina Tao, Zhang, Wenhui, Abouhossein, Mariam, Tole, Swati
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Springer Healthcare 2021
Aiheet:
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC8107167/
https://ncbi.nlm.nih.gov/pubmed/33778928
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s12325-021-01651-8
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!